Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84164 | 0.88 | DGAT1 (0.56) | DGAT1BRD4ALDH1A1HPGD | |
| SCHEMBL21645508 | 0.81 | DGAT1 (0.47) | DGAT1BRD4ALDH1A1HPGD | |
| SCHEMBL17810246 | 0.80 | DGAT1 (0.62) | DGAT1BRD4 | |
| SCHEMBL9638254 | 0.79 | DGAT1 (0.74) | DGAT1 | |
| SCHEMBL6982954 | 0.79 | DGAT1 (0.58) | DGAT1ALDH1A1HPGDTLR8 | |
| SCHEMBL12963688 | 0.79 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL27338948 | 0.78 | DGAT1 (0.54) | DGAT1BRD4 | |
| SCHEMBL28893810 | 0.77 | DGAT1 (0.45) | DGAT1ALDH1A1TLR8 | |
| SCHEMBL616813 | 0.77 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL68112 | 0.76 | DGAT1 (0.41) | DGAT1ALDH1A1HPGDGABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| CN-1378544-A | Substituted azoles compounds | NOVARTIS AG (CH) | 2002-11-06 | — | — | CN | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | DGAT1 2618/4885BRD4 2671/4885ALDH1A1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.